Search
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. … [L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy.
Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigationalDenileukin diftitox is an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met<sub>1</sub>-Thr<sub … >387</sub>)-His and the sequence for human interleukin-2 (IL-2; Ala<sub>1</sub>-Thr<sub>133</sub>).
Voacamine
go.drugbank.com/drugs/DB04877ExperimentalVoacamine is an alkaloid isolated from the bark of the _Pescheria fuchsiae folia_ tree. It is an antimalarial drug approved for use in several African countries. … Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells.
Categories: P-glycoprotein inhibitorsEcallantide
go.drugbank.com/drugs/DB05311ApprovedEcallantide is marketed by FDA and EMA under the trade name Kalbitor for subcutaneous injection. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]
Categories: Drugs for Constipation, Cytochrome P-450 SubstratesEntacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … [A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesHydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalThe FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.[L9025] … Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain.
Mixtures: P-TussCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigationalAvapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal … [A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib].
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesMechlorethamine
go.drugbank.com/drugs/DB00888ApprovedInvestigationalThe FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL … A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas.
Categories: Chemical Warfare Agents